The Game‑Changer for Recovery: How Journavx Ends the Fear of Pain Management on Naltrexone

For many individuals battling opioid addiction, the Naltrexone Implant has been a beacon of hope. By blocking the euphoric effects of opioids, it effectively dismantles the reward pathway, giving patients a powerful shield against cravings and relapse. The implant works continuously to keep opioid receptors in the brain occupied, meaning that even if a person uses opioids, they won’t feel the “high.” This protection significantly reduces the risk of a fatal overdose.

However, this life‑saving blockade created a major dilemma. For someone on a naltrexone implant, opioid receptors are effectively “turned off” for months at a time. But what happens when they have a dental emergency, a car accident, or need surgery? The standard pain medications—opioids—simply won’t work because there is nowhere for them to bind. This has been a leading cause of anxiety and even deterred some from seeking this life‑saving treatment.

• High‑Dose Opioids: In a hospital setting, doctors can try to overpower the blockade by administering very high doses of opioids. However, this is extremely risky. Because the patient is under constant monitoring by anesthesiologists, they can be watched for respiratory depression. This is not a solution for a routine dental visit.
• Implant Removal: It is possible to surgically remove the naltrexone implant to allow opioids to work again. However, this defeats the purpose of addiction treatment and leaves the patient vulnerable to cravings and relapse while they recover. Additionally, studies have shown that removal surgery itself presents a challenge; in one study of patients undergoing implant removal, 44% reported moderate to severe pain post‑operatively despite receiving general anesthesia, because the painkillers were blocked.

The Solution is Here: A New Kind of Painkiller

This is where the recent FDA approval of Journavx (suzetrigine) in January 2025 represents a monumental shift in the field of addiction medicine and pain management. Journavx is the first in a new class of non‑opioid painkillers, and crucially, it does not work on opioid receptors.

Here is how it solves the problem:

• It Works Differently: While opioids work in the brain, Journavx works in the periphery—at the site of the pain. It blocks a specific sodium channel (NaV1.8) that transmits pain signals from the nerves to the brain. Think of it as stopping the pain signal at the source rather than turning off the brain’s ability to feel the pain.
• It Bypasses Naltrexone: Because Journavx does not touch the opioid receptors in the brain, the presence of the naltrexone implant does not stop Journavx from working. The implant blocks one pathway (opioids), while Journavx works via an entirely different, unaffected pathway.
• It is Safe for Recovery: Journavx does not activate the brain’s reward centers. Clinical trials have not shown any evidence of addictive potential, euphoria, or respiratory depression associated with this drug. It allows the patient to get pain relief without triggering the relapse cycle.

A New Era for Patients in Recovery

For the first time, patients can approach medication‑assisted treatment (MAT) without the fear that a single accident will leave them in agony or force them to “break” their protection for pain relief. If a patient on a naltrexone implant needs a tooth pulled or suffers a broken bone, the healthcare provider now has a powerful, non‑opioid tool at their disposal.

This effectively removes one of the last major barriers to choosing naltrexone implants for addiction recovery. It gives patients the confidence to protect themselves against relapse, knowing that their future pain management needs have already been addressed by modern science.

Making This Information Known: A Simple Awareness Strategy

To reach the people who need it most, we need to speak directly to the fears of the patient and reassure the medical professional.

• Targeted Headlines: Use headlines that address the specific fear, such as: “Finally: A Safe Painkiller for People on Naltrexone.” or “Ending the ‘Pain Management’ Fear: Why Journavx Changes Everything for Recovery.”
• Social Media / Forum Strategy: Post in recovery subreddits, Facebook groups for MAT, and addiction medicine forums. The message should be: “If you were scared of the Naltrexone Implant because of pain emergencies, read this.”
• Patient Testimonial Angle: Frame the narrative around a patient who didn’t get the implant out of fear of needing dental work, and how they can now move forward without hesitation.
• Medical Community Outreach: Tailor a version for dentists and emergency room doctors. The title could be “Managing Acute Pain in Patients with OUD: What You Need to Know About Journavx.” This addresses the clinician’s anxiety about treating these complex patients.

Additional Clinical & Practical Context

How Journavx Actually Works – The Science

Journavx (suzetrigine) is a highly selective inhibitor of the voltage‑gated sodium channel 1.8 (NaV1.8). This channel is expressed almost exclusively in the peripheral nervous system and plays a critical role in transmitting pain signals from the site of injury to the spinal cord and brain. Because NaV1.8 has minimal to no expression in the central nervous system, the drug avoids the pathways associated with addiction, euphoria, and respiratory depression.

Clinical Evidence: What the Trials Show

In two Phase 3 trials involving more than 2,100 patients, a 48‑hour course of Journavx demonstrated a statistically significant reduction in pain intensity compared to placebo following bunionectomy and abdominoplasty procedures. The drug was generally well‑tolerated, with the most common adverse events being nausea, constipation, headache, pruritus, muscle spasms, increased creatine phosphokinase, and rash.

It is important to note that in head‑to‑head comparisons, Journavx did not demonstrate superiority over hydrocodone/acetaminophen in reducing pain. The key value of Journavx lies not in greater potency, but in its favorable safety profile and non‑addictive mechanism, making it suitable for patients in recovery. Additionally, no evidence of physical dependence or withdrawal was observed upon discontinuation.

Naltrexone Implant: Benefits and Known Challenges

While naltrexone implants improve treatment retention compared to oral naltrexone, studies show that approximately half of patients remain in treatment for six months. Ambivalence, side effects, and practical concerns contribute to discontinuation. Common side effects include headaches, nausea, fatigue, dizziness, and decreased appetite. Some patients report more significant issues such as anxiety, sexual dysfunction, or a feeling of being “blasé to the world.”

There have also been case reports of infection at the implant site requiring surgical intervention, severe withdrawal reactions, and psychiatric complications. The Australian Medical Association has called for more rigorous oversight and standardized protocols for naltrexone implants. Recent research suggests that placing the implant in the back region (rather than the abdomen) may lead to better adherence, fewer infections, and a lower rate of implant extrusion.

Practical Pain Management Guidance for Patients and Providers

For Patients: If you are on a naltrexone implant and need pain relief for a dental procedure, injury, or surgery, you should:

• Inform every healthcare provider (dentist, emergency room staff, surgeon) that you have a naltrexone implant.
• Discuss non‑opioid options such as Journavx, regional nerve blocks, or NSAIDs as appropriate.
• If opioid therapy is deemed absolutely necessary by the treating physician, it must be administered in a setting equipped for cardiopulmonary resuscitation and continuous monitoring, as you will be exquisitely sensitive to opioids once the blockade is reversed.

For Dentists and Emergency Clinicians: Patients on naltrexone implants can be safely managed using non‑opioid analgesics. Journavx is now a first‑line option for acute pain in this population. Traditional non‑opioid alternatives (NSAIDs, acetaminophen, regional anesthesia) may also be considered depending on the procedure and severity of pain. If reversal of naltrexone blockade is required for emergency opioid therapy, this must be performed in an anesthesia care setting by trained personnel.

Naltrexone Reversal – A Critical Safety Note

If naltrexone blockade must be reversed (e.g., to allow opioids to work in a life‑threatening emergency), this should only be attempted in a controlled hospital environment. The patient will have reduced opioid tolerance and will be highly sensitive to even standard doses, requiring close monitoring for respiratory depression. This is not a routine procedure and is not recommended for minor pain management.

Summary Table: Why Journavx is a Vital Tool for Recovery

This combination finally gives patients in recovery the best of both worlds: robust protection from addiction and guaranteed safety from pain.